There is crowded, and then there is courageous. Alzheimer’s is both. Into that arena walks Korsana Biosciences with $175M in venture backing and a point of view sharp enough to cut through plaque and...
There is crowded, and then there is courageous. Alzheimer’s is both. Into that arena walks Korsana Biosciences with $175M in venture backing and a point of view sharp enough to cut through plaque and polite skepticism.
Founded in 2024 with a $25M seed investment from Fairmount and Venrock Healthcare Capital Partners, Korsana Biosciences did not stumble out of a lab looking for attention. It was built with intent. The Series A followed in September 2025, a $150M private round co-led by Wellington Management and TCGX, with J.P. Morgan Life Sciences Private Capital, Janus Henderson Investors, Sanofi Ventures, Foresite Capital and others leaning in. When capital like that moves, it is not chasing noise. It is underwriting conviction.
Jonathan Violin, Ph.D., CEO, knows this terrain. Building Viridian Therapeutics, Dianthus Therapeutics and Quellis Biosciences into real assets before their next chapters is not résumé padding. It is pattern recognition. On the board, Nilesh Kumar, Head of Biotech Private Investments at Wellington Management, brings the long view. This is leadership that has seen molecules become markets.
Korsana Biosciences is developing blood brain barrier penetrant antibody therapeutics for neurodegenerative diseases, starting with Alzheimer’s. The lead program, KRSA 028, is a next generation shuttled anti amyloid beta antibody. The platform behind it is Therapeutic Targeting, or THETA, a proprietary shuttle leveraging transferrin receptor 1 and Fc engineering to drive biologics across the blood brain barrier. If the brain has been a gated community, THETA is the keycard designed by someone who studied the lock.
Only 2 disease modifying therapies have been approved for Alzheimer’s disease, both carrying safety warnings and modest efficacy with meaningful treatment burden. Meanwhile, the U.S. patient population is projected to approach 13M by 2050. Korsana Biosciences is capitalized through key clinical milestones in 2027 with runway into 2028. That is not just financing. That is time to execute.
KRSA 028 is engineered to enhance amyloid plaque clearance, reduce amyloid related imaging abnormalities and hematologic adverse events, and enable low volume subcutaneous administration. In a market where intravenous drips and safety debates dominate the conversation, convenience and control are not luxuries. They are leverage.
Discovered in partnership with Paragon Therapeutics, and described as the 7th company launched from Paragon discovered assets, Korsana Biosciences is not pretending to invent Alzheimer’s science from scratch. It is taking a validated pathway and asking a better delivery question.
Neurodegeneration is unforgiving. Capital is selective. When both align around a platform like THETA and a program like KRSA 028, it signals something more than another biotech headline. It hints at a future where crossing the blood brain barrier is not the exception, but the expectation.